| Old Articles: <Older 7471-7480 Newer> |
|---|
 |
The Motley Fool
May 24, 2011
Andrew Tonner |
Does Eli Lilly Deserve a Spot in Your Portfolio? A quick check of the numbers should help get us started.   |
The Motley Fool
May 24, 2011
Brian Orelli |
If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica. |
The Motley Fool
May 24, 2011
Brian Orelli |
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. |
The Motley Fool
May 23, 2011
Andrew Tonner |
Does Amgen Deserve a Spot in Your Portfolio? Depending on your assessment of future growth, Amgen could certainly make a nice addition to your portfolio. |
The Motley Fool
May 21, 2011
Seth Jayson |
One Reason the Street Should Love Novo Nordisk's Earnings On a 12-month basis, the cash conversion cycle trend at Novo Nordisk looks very good. |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
Chemistry World
May 20, 2011
Sarah Houlton |
Takeda expands into Europe with Nycomed deal Japanese pharma company Takeda is to acquire Swiss-headquartered rival Nycomed for 9.6 billion. If the antitrust authorities give the go-ahead, the takeover should be completed by late summer. |
The Motley Fool
May 20, 2011
Brian Orelli |
Abbott Hits a Triple Not a home run, but Trilipix will likely stay on the market. |
The Motley Fool
May 20, 2011
Arlene Weintrab. |
Miller Tabak Fund Manager Says Investors Are Ignoring the Upsides in Healthcare This manager says investors in 2013 are going to look back and wish they had invested more in healthcare funds today. |
BusinessWeek
May 19, 2011
Alexandra Wolfe |
A Killer App for Doctor's Appointments A medical emergency inspired a McKinsey consultant to create a health-care business, ZocDoc, an OpenTable for medical appointments.. |
| <Older 7471-7480 Newer> Return to current articles. |
